In conclusion, this study demonstrated that a favorable survival prognosis was identified in EGFR‐mutant NSCLC patients with BMs with Lung‐mol GPA ≥3 who were treated with afatinib or erlotinib in combination with SRS. This evidence concerns the gene EGFR and non-small cell lung carcinoma.